Revolution Medicines (Nasdaq: RVMD) reported no revenue for Q2 2026 and a diluted net loss of $3.06 per share, compared with $1.31 a year earlier; net loss widened to $644.4 million from $247.8 million. The quarter combined FDA acceptance of daraxonrasib’s pancreatic cancer application with sharply higher clinical development, manufacturing and commercial-readiness spending.
Core financial results
Research and development expense increased about 76% as Revolution Medicines spent more on daraxonrasib and zoldonrasib trials and manufacturing, expanded headcount and recorded higher stock-based compensation. G&A expense nearly tripled, reflecting stock-based compensation, additional personnel, commercial preparation and administrative costs.
The net loss grew faster than the operating loss because Q2 2026 included a $151.0 million non-cash charge from revaluing warrants assumed in the EQRx acquisition, compared with a $4.6 million charge a year earlier.
| Metric | Q2 2026 | Q2 2025 | Year-over-year change |
|---|---|---|---|
| R&D expense | $394.9 million | $224.1 million | +76.2% |
| G&A expense | $110.2 million | $40.6 million | +171.6% |
| Total operating expense | $505.1 million | $264.7 million | +90.8% |
| Operating loss | $505.1 million | $264.7 million | Loss widened 90.8% |
| Net loss | $644.4 million | $247.8 million | Loss widened 160.1% |
| Diluted net loss per share | $3.06 | $1.31 | Loss widened 133.6% |
Clinical and regulatory progress
Daraxonrasib was the quarter’s most important program. The FDA accepted its New Drug Application for previously treated metastatic pancreatic ductal adenocarcinoma after the Phase 3 RASolute 302 trial showed statistically significant improvements in overall survival and progression-free survival versus chemotherapy. The company also established U.S. launch infrastructure and began a phased European regulatory review.
Early lung cancer combination results provided support for additional Phase 3 development, although the datasets remain relatively small and follow-up is limited.
| Program | Q2 development | Next disclosed step |
|---|---|---|
| Daraxonrasib in pancreatic cancer | FDA accepted the NDA; drug distributed through expanded access on behalf of more than 2,000 patients; EMA began phased review | Regulatory review and continued Phase 3 studies in first-line metastatic and adjuvant disease |
| Daraxonrasib in NSCLC | Received FDA Breakthrough Therapy Designation for certain previously treated metastatic RAS-mutant NSCLC patients | RASolve 301 enrollment expected to finish in 2026, with an initial readout anticipated in 2027 |
| Zoldonrasib combination in first-line NSCLC | 82% confirmed and pending-confirmation response rate and 100% disease control rate among 28 evaluable patients; median follow-up was 3.4 months | Global Phase 3 RASolve 308 has begun |
| Elironrasib combination in first-line NSCLC | 85% confirmed response rate, 97% disease control rate and 95% progression-free at six months among 39 patients; median follow-up was 8.7 months | Phase 3 RASolve 307 planned to start in Q4 2026 |
Zoldonrasib also generated preliminary pancreatic cancer combination data supporting the ongoing RASolute 305 and newly initiated RASolute 309 Phase 3 trials. All of Revolution Medicines’ product candidates remain investigational and unapproved.
Profitability, liquidity and the balance sheet
Cash, cash equivalents and marketable securities reached $3.94 billion at June 30, 2026, up by approximately $1.91 billion from December 31, 2025. Working capital increased to $3.67 billion from $1.78 billion over the same period.
The increase primarily reflects external financing rather than operating profitability. Revolution Medicines raised $2.23 billion in gross proceeds through April offerings of common stock and 0.50% convertible senior notes, followed by a $250 million Royalty Pharma payment in May. Up to another $1.5 billion remains committed under the Royalty Pharma arrangements, subject to specific milestones.
This financing provides resources for an expanding Phase 3 portfolio and potential commercialization, but the higher expense base shows that regulatory progress is moving the company into a more costly development and launch-preparation period.
2026 expense guidance
Revolution Medicines updated its full-year 2026 GAAP operating expense guidance to $2.1 billion to $2.2 billion. The prior range was not included in the source material, so the size of the revision cannot be calculated.
| Metric | Latest outlook | Interpretation |
|---|---|---|
| Full-year 2026 GAAP operating expense | $2.1 billion-$2.2 billion | Updated company guidance |
| Stock-based compensation included in operating expense | $270 million-$290 million | Non-cash expense |
| Implied second-half operating expense | Approximately $1.15 billion-$1.25 billion | Derived from first-half expense of $950.4 million |
The implied second-half range is approximately 21% to 32% above first-half operating expense, indicating that spending is expected to accelerate as late-stage trials and commercialization work continue.
Risks investors should monitor
- Regulatory uncertainty: FDA acceptance of the daraxonrasib application starts the review process but does not guarantee approval or determine the timing and conditions of any approval.
- Early lung cancer evidence: The zoldonrasib and elironrasib combination results came from small patient groups with limited follow-up, particularly the 3.4-month median follow-up for zoldonrasib.
- Rising operating costs: Updated guidance implies meaningfully higher second-half spending, increasing the importance of executing clinical, manufacturing and commercial plans on schedule.
- Accounting volatility: Changes in the EQRx warrant liability added a $151.0 million non-cash charge in Q2 and may continue to create differences between operating performance and reported net loss.
- Multi-program execution: Revolution Medicines is simultaneously conducting several Phase 3 trials, preparing a potential launch and building international capabilities, increasing operational complexity.
Summary
Revolution Medicines’ Q2 2026 results were defined by daraxonrasib’s move into regulatory review and the company’s transition toward potential commercialization. That progress came with substantially higher research, manufacturing, personnel and launch-preparation costs, while a non-cash warrant charge further widened the reported loss. The main issues ahead are the outcome of the daraxonrasib review, the maturation of early lung cancer combination data and the company’s ability to manage an accelerating expense base across multiple late-stage programs.
Find out more
Comments